COAGHemab Therapeutics Holdings, Inc.

HealthcareUSD
$27.72

The financials

Hemab Therapeutics Holdings, Inc. by the numbers

Hemab Therapeutics Holdings, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$26M−$17Mn/a
Net income−$24M−$15Mn/a
Diluted EPS−$0.80−$16.18n/a

Biotechnology

The closest names by size in the same industry

Compare peers
IMTX-4.9%
Immatics N.V.
AVLN-3.7%
Avalyn Pharma Inc.
JBIO-0.41%
Jade Biosciences, Inc.
SVRA+3.4%
Savara Inc.
MNKD+2.3%
MannKind Corporation
DMRA+2.6%
Damora Therapeutics, Inc.